Voltage-gated sodium channels: Mutations, channelopathies and targets

Current Medicinal Chemistry

Volumn 18, Issue 3, 2011, Pages 377-397

  Andavan, G S B ^a   Lemmens Gruber, R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Channelopathy; Sodium channel mutations; Sodium channel subtypes; Subtype selective sodium channel blockers; Subtype selective sodium channel toxins; Voltage gated sodium channel

Indexed keywords

ACONITINE; BATRACHOTOXIN; BREVETOXIN; CIGUATOXIN; CONOTOXIN; GRAYANOTOXIN; SAXITOXIN; SCORPION VENOM; SEA ANEMONE TOXIN; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SPIDER VENOM; TETRODOTOXIN; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL; WASP VENOM;

ACTION POTENTIAL; ARTICLE; BRUGADA SYNDROME; CHROMOSOME 17Q; DISEASE ASSOCIATION; LONG QT SYNDROME; MUTATION; NERVE CONDUCTION DISORDER; NEUROPATHIC PAIN; NONHUMAN; SICK SINUS SYNDROME; SKELETAL MUSCLE; SODIUM CHANNELOPATHY; SUDDEN INFANT DEATH SYNDROME;

EID: 79251472730     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794839133     Document Type: Article

References (264)

1. Mandel, G. Tissue-specific expression of the voltage-sensitive sodium channel. J. Membr. Biol., 1992, 125(3), 193-205.
2. Catterall, W.A. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron, 2000, 26(1), 13-25.
3. Yu, F.H.; Catterall, W.A. Overview of the voltage-gated sodium channel family. Genome Biol., 2003, 4(3), 207.
4. Fahmi, A.I.; Patel, M.; Stevens, E.B.; Fowden, A.L.; John, J.E., 3rd; Lee, K.; Pinnock, R.; Morgan, K.; Jackson, A.P.; Vandenberg, J.I. The sodium channel beta-subunit SCN3b modulates the kinetics of SCN5a and is expressed heterogeneously in sheep heart. J. Physiol., 2001, 537(Pt 3), 693-700.
5. Isom, L.L.; De Jongh, K.S.; Catterall, W.A. Auxiliary subunits of voltage-gated ion channels. Neuron, 1994, 12(6), 1183-1194.
6. Isom, L.L.; De Jongh, K.S.; Patton, D.E.; Reber, B.F.; Offord, J.; Charbonneau, H.; Walsh, K.; Goldin, A.L.; Catterall, W.A. Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. Science, 1992, 256(5058), 839-842.
7. Isom, L.L.; Ragsdale, D.S.; De Jongh, K.S.; Westenbroek, R.E.; Reber, B.F.; Scheuer, T.; Catterall, W.A. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell, 1995, 83(3), 433-442.
8. Morgan, K.; Stevens, E.B.; Shah, B.; Cox, P.J.; Dixon, A.K.; Lee, K.; Pinnock, R.D.; Hughes, J.; Richardson, P.J.; Mizuguchi, K.; Jackson, A.P. Beta 3: An additional auxiliary subunit of the voltagesensitive sodium channel that modulates channel gating with distinct kinetics. Proc. Natl. Acad. Sci. USA, 2000, 97(5), 2308-2313.
9. Isom, L.L. Sodium channel beta subunits: Anything but auxiliary. Neuroscientist, 2001, 7(1), 42-54.
10. Zhou, J.; Yi, J.; Hu, N.; George, A.L., Jr.; Murray, K.T. Activation of protein kinase A modulates trafficking of the human cardiac sodium channel in Xenopus oocytes. Circ. Res., 2000, 87(1), 33-38.
11. Kass, R.S. Sodium channel inactivation in heart: A novel role of the carboxy-terminal domain. J. Cardiovasc. Electrophysiol., 2006, 17 (Suppl 1), S21-S25.
12. Ren, D.; Navarro, B.; Xu, H.; Yue, L.; Shi, Q.; Clapham, D.E. A prokaryotic voltage-gated sodium channel. Science, 2001, 294(5550), 2372-2375.
13. Heinemann, S.H.; Terlau, H.; Stuhmer, W.; Imoto, K.; Numa, S. Calcium channel characteristics conferred on the sodium channel by single mutations. Nature, 1992, 356(6368), 441-443.
14. Hodgkin, A.L.; Huxley, A.F. Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo. J. Physiol., 1952, 116(4), 449-472.
15. George, A.L., Jr. Inherited disorders of voltage-gated sodium channels. J. Clin. Invest., 2005, 115(8), 1990-1999.
16. Vilin, Y.Y.; Ruben, P.C. Slow inactivation in voltage-gated sodium channels: Molecular substrates and contributions to channelopathies. Cell Biochem. Biophys., 2001, 35(2), 171-190.
17. Catterall, W.A. Structure and function of voltage-gated sodium and calcium channels. Curr. Opin. Neurobiol., 1991, 1(1), 5-13.
18. Denac, H.; Mevissen, M.; Scholtysik, G. Structure, function and pharmacology of voltage-gated sodium channels. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362(6), 453-479.
19. Marban, E.; Yamagishi, T.; Tomaselli, G.F. Structure and function of voltage-gated sodium channels. J. Physiol., 1998, 508(Pt 3), 647-657.
20. Yang, N.; George, A.L., Jr.; Horn, R. Molecular basis of charge movement in voltage-gated sodium channels. Neuron, 1996, 16(1), 113-122.
21. Kuhn, F.J.; Greeff, N.G. Movement of voltage sensor S4 in domain 4 is tightly coupled to sodium channel fast inactivation and gating charge immobilization. J. Gen. Physiol., 1999, 114(2), 167-183.
22. Mitrovic, N.; George, A.L., Jr.; Lerche, H.; Wagner, S.; Fahlke, C.; Lehmann-Horn, F. Different effects on gating of three myotoniacausing mutations in the inactivation gate of the human muscle sodium channel. J. Physiol., 1995, 487(Pt 1), 107-114.
23. Tomaselli, G.F.; Chiamvimonvat, N.; Nuss, H.B.; Balser, J.R.; Perez-Garcia, M.T.; Xu, R.H.; Orias, D.W.; Backx, P.H.; Marban, E. A mutation in the pore of the sodium channel alters gating. Biophys. J., 1995, 68(5), 1814-1827.
24. French, R.J.; Horn, R. Sodium channel gating: Models, mimics, and modifiers. Annu. Rev. Biophys. Bioeng., 1983, 12, 319-356.
25. Romine, W.O., Jr.; Schoepfle, G.M.; Smythies, J.R.; Al-Zahid, G.; Bradley, R.J. Pharmacological evidence related to the existence of two sodium channel gating mechanisms. Nature, 1974, 248(5451), 797-799.
26. Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev., 2005, 57(4), 397-409.
27. Malo, M.S.; Blanchard, B.J.; Andresen, J.M.; Srivastava, K.; Chen, X.N.; Li, X.; Jabs, E.W.; Korenberg, J.R.; Ingram, V.M. Localization of a putative human brain sodium channel gene (SCN1A) to chromosome band 2q24. Cytogenet. Cell Genet., 1994, 67(3), 178-186.
28. Goldin, A.L. Resurgence of sodium channel research. Annu. Rev. Physiol., 2001, 63, 871-894.
29. Satin, J.; Kyle, J.W.; Chen, M.; Bell, P.; Cribbs, L.L.; Fozzard, H.A.; Rogart, R.B. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science, 1992, 256(5060), 1202-1205.
30. Sivilotti, L.; Okuse, K.; Akopian, A.N.; Moss, S.; Wood, J.N. A single serine residue confers tetrodotoxin insensitivity on the rat sensory-neuron-specific sodium channel SNS. FEBS Lett., 1997, 409(1), 49-52.
31. Rogers, M.; Tang, L.; Madge, D.J.; Stevens, E.B. The role of sodium channels in neuropathic pain. Semin. Cell Dev. Biol., 2006, 17(5), 571-581.
32. Tan, B.H.; Valdivia, C.R.; Rok, B.A.; Ye, B.; Ruwaldt, K.M.; Tester, D.J.; Ackerman, M.J.; Makielski, J.C. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm, 2005, 2(7), 741-747.
33. Makielski, J.C.; Ye, B.; Valdivia, C.R.; Pagel, M.D.; Pu, J.; Tester, D.J.; Ackerman, M.J. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ. Res., 2003, 93(9), 821-828.
34. Kerr, N.C.; Holmes, F.E.; Wynick, D. Novel mRNA isoforms of the sodium channels Na(v)1.2, Na(v)1.3 and Na(v)1.7 encode predicted two-domain, truncated proteins. Neuroscience, 2008, 155(3), 797-808.
35. Choi, J.S.; Cheng, X.; Foster, E.; Leffler, A.; Tyrrell, L.; Te Morsche, R.H.; Eastman, E.M.; Jansen, H.J.; Huehne, K.; Nau, C.; Dib- Hajj, S.D.; Drenth, J.P.; Waxman, S.G. Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. Brain, 2010, 133(6), 1823-1835.
36. Schroeter, A.; Walzik, S.; Blechschmidt, S.; Haufe, V.; Benndorf, K.; Zimmer, T. Structure and function of splice variants of the cardiac voltage-gated sodium channel Na(v)1.5. J. Mol. Cell. Cardiol., 2010, 49(1), 16-24.
37. Gazina, E.V.; Richards, K.L.; Mokhtar, M.B.; Thomas, E.A.; Reid, C.A.; Petrou, S. Differential expression of exon 5 splice variants of sodium channel alpha subunit mRNAs in the developing mouse brain. Neuroscience, 2010, 166(1), 195-200.
38. Schirmeyer, J.; Szafranski, K.; Leipold, E.; Mawrin, C.; Platzer, M.; Heinemann, S.H. A subtle alternative splicing event of the Na(V)1.8 voltage-gated sodium channel is conserved in human, rat, and mouse. J. Mol. Neurosci., 2010, 41(2), 310-314.
39. Lossin, C. A catalog of SCN1A variants. Brain Dev., 2009, 31(2), 114-130.
40. Stafstrom, C.E. Severe epilepsy syndromes of early childhood: The link between genetics and pathophysiology with a focus on SCN1A mutations. J. Child Neurol., 2009, 24(Suppl 8), 15S-23S.
41. Hedley, P.L.; Jorgensen, P.; Schlamowitz, S.; Moolman-Smook, J.; Kanters, J.K.; Corfield, V.A.; Christiansen, M. The genetic basis of Brugada syndrome: A mutation update. Hum. Mutat., 2009, 30(9), 1256-1266.
42. Ruan, Y.; Liu, N.; Priori, S.G. Sodium channel mutations and arrhythmias. Nat. Rev. Cardiol., 2009, 6(5), 337-348.
43. Zimmer, T.; Surber, R. SCN5A channelopathies-an update on mutations and mechanisms. Prog. Biophys. Mol. Biol., 2008, 98(2- 3), 120-136.
44. Vicart, S.; Sternberg, D.; Fontaine, B.; Meola, G. Human skeletal muscle sodium channelopathies. Neurol. Sci., 2005, 26(4), 194-202.
45. Heron, S.E.; Scheffer, I.E.; Berkovic, S.F.; Dibbens, L.M.; Mulley, J.C. Channelopathies in idiopathic epilepsy. Neurotherapeutics, 2007, 4(2), 295-304.
46. Herlenius, E.; Heron, S.E.; Grinton, B.E.; Keay, D.; Scheffer, I.E.; Mulley, J.C.; Berkovic, S.F. SCN2A mutations and benign familial neonatal-infantile seizures: The phenotypic spectrum. Epilepsia, 2007, 48(6), 1138-1142.
47. Misra, S.N.; Kahlig, K.M.; George, A.L., Jr. Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia, 2008, 49(9), 1535-1545.
48. Sugawara, T.; Tsurubuchi, Y.; Agarwala, K.L.; Ito, M.; Fukuma, G.; Mazaki-Miyazaki, E.; Nagafuji, H.; Noda, M.; Imoto, K.; Wada, K.; Mitsudome, A.; Kaneko, S.; Montal, M.; Nagata, K.; Hirose, S.; Yamakawa, K. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl. Acad. Sci. USA., 2001, 98(11), 6384-6389.
49. Chen, Y.H.; Dale, T.J.; Romanos, M.A.; Whitaker, W.R.; Xie, X.M.; Clare, J.J. Cloning, distribution and functional analysis of the type III sodium channel from human brain. Eur. J. Neurosci., 2000, 12(12), 4281-4289.
50. Cummins, T.R.; Waxman, S.G. Downregulation of tetrodotoxinresistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci., 1997, 17(10), 3503-3514.
51. Heine, R.; Pika, U.; Lehmann-Horn, F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum. Mol. Genet., 1993, 2(9), 1349-1353.
52. Orrell, R.W.; Jurkat-Rott, K.; Lehmann-Horn, F.; Lane, R.J. Familial cramp due to potassium-aggravated myotonia. J. Neurol. Neurosurg. Psychiatry, 1998, 65(4), 569-572.
53. Koch, M.C.; Baumbach, K.; George, A.L.; Ricker, K. Paramyotonia congenita without paralysis on exposure to cold: A novel mutation in the SCN4A gene (Val1293Ile). Neuroreport, 1995, 6(15), 2001-2004.
54. Ptacek, L.J.; George, A.L., Jr.; Barchi, R.L.; Griggs, R.C.; Riggs, J.E.; Robertson, M.; Leppert, M.F. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron, 1992, 8(5), 891-897.
55. Wu, F.F.; Takahashi, M.P.; Pegoraro, E.; Angelini, C.; Colleselli, P.; Cannon, S.C.; Hoffman, E.P. A new mutation in a family with cold-aggravated myotonia disrupts Na(+) channel inactivation. Neurology, 2001, 56(7), 878-884.
56. Bendahhou, S.; Cummins, T.R.; Tawil, R.; Waxman, S.G.; Ptacek, L.J. Activation and inactivation of the voltage-gated sodium channel: Role of segment S5 revealed by a novel hyperkalaemic periodic paralysis mutation. J. Neurosci., 1999, 19(12), 4762-4771.
57. Ptacek, L.J.; Gouw, L.; Kwiecinski, H.; McManis, P.; Mendell, J.R.; Barohn, R.J.; George, A.L., Jr.; Barchi, R.L.; Robertson, M.; Leppert, M.F. Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis. Ann. Neurol., 1993, 33(3), 300-307.
58. Bendahhou, S.; Cummins, T.R.; Hahn, A.F.; Langlois, S.; Waxman, S.G.; Ptacek, L.J. A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation. J. Clin. Invest., 2000, 106(3), 431-438.
59. Bulman, D.E.; Scoggan, K.A.; van Oene, M.D.; Nicolle, M.W.; Hahn, A.F.; Tollar, L.L.; Ebers, G.C. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology, 1999, 53(9), 1932-1936.
60. Davies, N.P.; Eunson, L.H.; Samuel, M.; Hanna, M.G. Sodium channel gene mutations in hypokalemic periodic paralysis: An uncommon cause in the UK. Neurology, 2001, 57(7), 1323-1325.
61. Bennett, P.B.; Yazawa, K.; Makita, N.; George, A.L., Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature, 1995, 376(6542), 683-685.
62. Goldenberg, I.; Moss, A.J. Long QT syndrome. J. Am. Coll. Cardiol., 2008, 51(24), 2291-2300.
63. Heron, S.E.; Hernandez, M.; Edwards, C.; Edkins, E.; Jansen, F.E.; Scheffer, I.E.; Berkovic, S.F.; Mulley, J.C. Neonatal seizures and Long QT Syndrome: A cardiocerebral channelopathy? Epilepsia, 2010, 51(2), 293-296.
64. Benito, B.; Brugada, J.; Brugada, R.; Brugada, P. Brugada syndrome. Rev. Esp. Cardiol., 2009, 62(11), 1297-1315.
65. Brugada, P.; Benito, B.; Brugada, R.; Brugada, J. Brugada syndrome: Update 2009. Hellenic J. Cardiol., 2009, 50(5), 352-372.
66. Chen, Q.; Kirsch, G.E.; Zhang, D.; Brugada, R.; Brugada, J.; Brugada, P.; Potenza, D.; Moya, A.; Borggrefe, M.; Breithardt, G.; Ortiz- Lopez, R.; Wang, Z.; Antzelevitch, C.; O'Brien, R.E.; Schulze- Bahr, E.; Keating, M.T.; Towbin, J.A.; Wang, Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature, 1998, 392(6673), 293-296.
67. Schott, J.J.; Alshinawi, C.; Kyndt, F.; Probst, V.; Hoorntje, T.M.; Hulsbeek, M.; Wilde, A.A.; Escande, D.; Mannens, M.M.; Le Marec, H. Cardiac conduction defects associate with mutations in SCN5A. Nat. Genet., 1999, 23(1), 20-21.
68. Benson, D.W.; Wang, D.W.; Dyment, M.; Knilans, T.K.; Fish, F.A.; Strieper, M.J.; Rhodes, T.H.; George, A.L., Jr. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest., 2003, 112(7), 1019-1028.
69. Lei, M.; Huang, C.L.; Zhang, Y. Genetic Na+ channelopathies and sinus node dysfunction. Prog. Biophys. Mol. Biol., 2008, 98(2-3), 171-178.
70. Makielski, J.C. SIDS: Genetic and environmental influences may cause arrhythmia in this silent killer. J. Clin. Invest., 2006, 116(2), 297-299.
71. Skinner, J.R.; Chung, S.K.; Montgomery, D.; McCulley, C.H.; Crawford, J.; French, J.; Rees, M.I. Near-miss SIDS due to Brugada syndrome. Arch. Dis. Child., 2005, 90(5), 528-529.
72. Wedekind, H.; Bajanowski, T.; Friederich, P.; Breithardt, G.; Wulfing, T.; Siebrands, C.; Engeland, B.; Monnig, G.; Haverkamp, W.; Brinkmann, B.; Schulze-Bahr, E. Sudden infant death syndrome and long QT syndrome: An epidemiological and genetic study. Int. J. Legal. Med., 2006, 120(3), 129-137.
73. Ellinor, P.T.; Nam, E.G.; Shea, M.A.; Milan, D.J.; Ruskin, J.N.; MacRae, C.A. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm, 2008, 5(1), 99-105.
74. McNair, W.P.; Ku, L.; Taylor, M.R.; Fain, P.R.; Dao, D.; Wolfel, E.; Mestroni, L. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation, 2004, 110(15), 2163-2167.
75. Olson, T.M.; Michels, V.V.; Ballew, J.D.; Reyna, S.P.; Karst, M.L.; Herron, K.J.; Horton, S.C.; Rodeheffer, R.J.; Anderson, J.L. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA, 2005, 293(4), 447-454.
76. Kohrman, D.C.; Smith, M.R.; Goldin, A.L.; Harris, J.; Meisler, M.H. A missense mutation in the sodium channel Scn8a is responsible for cerebellar ataxia in the mouse mutant jolting. J. Neurosci., 1996, 16(19), 5993-5999.
77. Drenth, J.P.; te Morsche, R.H.; Guillet, G.; Taieb, A.; Kirby, R.L.; Jansen, J.B. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J. Invest. Dermatol., 2005, 124(6), 1333-1338.
78. Han, C.; Rush, A.M.; Dib-Hajj, S.D.; Li, S.; Xu, Z.; Wang, Y.; Tyrrell, L.; Wang, X.; Yang, Y.; Waxman, S.G. Sporadic onset of erythermalgia: A gain-of-function mutation in Nav1.7. Ann. Neurol., 2006, 59(3), 553-558.
79. Harty, T.P.; Dib-Hajj, S.D.; Tyrrell, L.; Blackman, R.; Hisama, F.M.; Rose, J.B.; Waxman, S.G. Na(V)1.7 mutant A863P in erythromelalgia: Effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J. Neurosci., 2006, 26(48), 12566-12575.
80. Yang, Y.; Wang, Y.; Li, S.; Xu, Z.; Li, H.; Ma, L.; Fan, J.; Bu, D.; Liu, B.; Fan, Z.; Wu, G.; Jin, J.; Ding, B.; Zhu, X.; Shen, Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet., 2004, 41(3), 171-174.
81. Fertleman, C.R.; Baker, M.D.; Parker, K.A.; Moffatt, S.; Elmslie, F.V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J.N.; Gardiner, R.M.; Rees, M. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron, 2006, 52(5), 767-774.
82. Cox, J.J.; Reimann, F.; Nicholas, A.K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al- Gazali, L.; Hamamy, H.; Valente, E.M.; Gorman, S.; Williams, R.; McHale, D.P.; Wood, J.N.; Gribble, F.M.; Woods, C.G. An SCN9A channelopathy causes congenital inability to experience pain. Nature, 2006, 444(7121), 894-898.
83. Boucher, T.J.; Okuse, K.; Bennett, D.L.; Munson, J.B.; Wood, J.N.; McMahon, S.B. Potent analgesic effects of GDNF in neuropathic pain states. Science, 2000, 290(5489), 124-127.
84. Coward, K.; Plumpton, C.; Facer, P.; Birch, R.; Carlstedt, T.; Tate, S.; Bountra, C.; Anand, P. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain, 2000, 85(1-2), 41-50.
85. Dib-Hajj, S.D.; Tyrrell, L.; Black, J.A.; Waxman, S.G. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc. Natl. Acad. Sci. USA, 1998, 95(15), 8963-8968.
86. Eriksson, J.; Jablonski, A.; Persson, A.K.; Hao, J.X.; Kouya, P.F.; Wiesenfeld-Hallin, Z.; Xu, X.J.; Fried, K. Behavioral changes and trigeminal ganglion sodium channel regulation in an orofacial neuropathic pain model. Pain, 2005, 119(1-3), 82-94.
87. Abe, M.; Kurihara, T.; Han, W.; Shinomiya, K.; Tanabe, T. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine, 2002, 27(14), 1517-1525.
88. Shi, X.; Yasumoto, S.; Nakagawa, E.; Fukasawa, T.; Uchiya, S.; Hirose, S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain. Dev., 2009, 31(10), 758-762.
89. Kamiya, K.; Kaneda, M.; Sugawara, T.; Mazaki, E.; Okamura, N.; Montal, M.; Makita, N.; Tanaka, M.; Fukushima, K.; Fujiwara, T.; Inoue, Y.; Yamakawa, K. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J. Neurosci., 2004, 24(11), 2690-2698.
90. Striano, P.; Bordo, L.; Lispi, M.L.; Specchio, N.; Minetti, C.; Vigevano, F.; Zara, F. A novel SCN2A mutation in family with benign familial infantile seizures. Epilepsia, 2006, 47(1), 218-220.
91. Lakhan, R.; Kumari, R.; Misra, U.K.; Kalita, J.; Pradhan, S.; Mittal, B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol., 2009, 68(2), 214-220.
92. Ogiwara, I.; Ito, K.; Sawaishi, Y.; Osaka, H.; Mazaki, E.; Inoue, I.; Montal, M.; Hashikawa, T.; Shike, T.; Fujiwara, T.; Inoue, Y.; Kaneda, M.; Yamakawa, K. De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology, 2009, 73(13), 1046-1053.
93. McClatchey, A.I.; Van den Bergh, P.; Pericak-Vance, M.A.; Raskind, W.; Verellen, C.; McKenna-Yasek, D.; Rao, K.; Haines, J.L.; Bird, T.; Brown, R.H., Jr. Temperature-sensitive mutations in the III-IV cytoplasmic loop region of the skeletal muscle sodium channel gene in paramyotonia congenita. Cell, 1992, 68(4), 769-774.
94. Ptacek, L.J.; George, A.L., Jr.; Griggs, R.C.; Tawil, R.; Kallen, R.G.; Barchi, R.L.; Robertson, M.; Leppert, M.F. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell, 1991, 67(5), 1021-1027.
95. Rojas, C.V.; Wang, J.Z.; Schwartz, L.S.; Hoffman, E.P.; Powell, B.R.; Brown, R.H., Jr. A Met-to-Val mutation in the skeletal muscle Na+ channel alpha-subunit in hyperkalaemic periodic paralysis. Nature, 1991, 354(6352), 387-389.
96. Sternberg, D.; Maisonobe, T.; Jurkat-Rott, K.; Nicole, S.; Launay, E.; Chauveau, D.; Tabti, N.; Lehmann-Horn, F.; Hainque, B.; Fontaine, B. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain, 2001, 124(Pt 6), 1091-1099.
97. Cannon, S.C. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. Kidney. Int., 2000, 57(3), 772-779.
98. Fournier, E.; Arzel, M.; Sternberg, D.; Vicart, S.; Laforet, P.; Eymard, B.; Willer, J.C.; Tabti, N.; Fontaine, B. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann. Neurol., 2004, 56(5), 650-661.
99. Luan, X.; Chen, B.; Liu, Y.; Zheng, R.; Zhang, W.; Yuan, Y. Tubular aggregates in paralysis periodica paramyotonica with T704M mutation of SCN4A. Neuropathology, 2009, 29(5), 579-584.
100. Petitprez, S.; Tiab, L.; Chen, L.; Kappeler, L.; Rosler, K.M.; Schorderet, D.; Abriel, H.; Burgunder, J.M. A novel dominant mutation of the Nav1.4 alpha-subunit domain I leading to sodium channel myotonia. Neurology, 2008, 71(21), 1669-1675.
101. Lee, S.C.; Kim, H.S.; Park, Y.E.; Choi, Y.C.; Park, K.H.; Kim, D.S. Clinical Diversity of SCN4A-Mutation-Associated Skeletal Muscle Sodium Channelopathy. J. Clin. Neurol., 2009, 5(4), 186-191.
102. Hoffman, B.F.; Cranefield, P.F. Electrophysiology of the Heart. McGraw-Hill: New York, 1960.
103. Hondeghem, L.M.; Katzung, B.G. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim. Biophys. Acta., 1977, 472(3-4), 373-398.
104. Grant, A.O.; Starmer, C.F.; Strauss, H.C. Antiarrhythmic drug action. Blockade of the inward sodium current. Circ. Res., 1984, 55(4), 427-439.
105. Cascio, W.E. Myocardial ischemia: What factors determine arrhythmogenesis? J. Cardiovasc. Electrophysiol., 2001, 12(6), 726-729.
106. Tomaselli, G.F.; Zipes, D.P. What causes sudden death in heart failure? Circ. Res., 2004, 95(8), 754-763.
107. Brugada, P.; Brugada, J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J. Am. Coll. Cardiol., 1992, 20(6), 1391-1396.
108. Veltmann, C.; Schimpf, R.; Echternach, C.; Eckardt, L.; Kuschyk, J.; Streitner, F.; Spehl, S.; Borggrefe, M.; Wolpert, C. A prospective study on spontaneous fluctuations between diagnostic and nondiagnostic ECGs in Brugada syndrome: Implications for correct phenotyping and risk stratification. Eur. Heart J., 2006, 27(21), 2544-2552.
109. Brugada, J.; Brugada, R.; Brugada, P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J. Electrocardiol., 2000, 33 (Suppl), 41-47.
110. Nademanee, K.; Veerakul, G.; Mower, M.; Likittanasombat, K.; Krittayapong, R.; Bhuripanyo, K.; Sitthisook, S.; Chaothawee, L.; Lai, M.Y.; Azen, S.P. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): A randomized clinical trial. Circulation, 2003, 107(17), 2221-2226.
111. Mizusawa, Y.; Sakurada, H.; Nishizaki, M.; Hiraoka, M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: Low-dose quinidine therapy as an adjunctive treatment. J. Cardiovasc. Pharmacol., 2006, 47(3), 359-364.
112. Belhassen, B.; Glick, A.; Viskin, S. Efficacy of quinidine in highrisk patients with Brugada syndrome. Circulation, 2004, 110(13), 1731-1737.
113. Alings, M.; Wilde, A. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation, 1999, 99(5), 666-673.
114. Chiang, K.C.; Lai, L.P.; Shieh, R.C. Characterization of a novel Nav1.5 channel mutation, A551T, associated with Brugada syndrome. J. Biomed. Sci., 2009, 16, 76.
115. Antzelevitch, C.; Nof, E. Brugada syndrome: Recent advances and controversies. Curr. Cardiol. Rep., 2008, 10(5), 376-383.
116. Meregalli, P.G.; Tan, H.L.; Probst, V.; Koopmann, T.T.; Tanck, M.W.; Bhuiyan, Z.A.; Sacher, F.; Kyndt, F.; Schott, J.J.; Albuisson, J.; Mabo, P.; Bezzina, C.R.; Le Marec, H.; Wilde, A.A. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm, 2009, 6(3), 341-348.
117. Hsueh, C.H.; Chen, W.P.; Lin, J.L.; Tsai, C.T.; Liu, Y.B.; Juang, J.M.; Tsao, H.M.; Su, M.J.; Lai, L.P. Distinct functional defect of three novel Brugada syndrome related cardiac sodium channel mutations. J. Biomed. Sci., 2009, 16, 23.
118. Kotta, C.M.; Anastasakis, A.; Gatzoulis, K.; Manolis, A.S.; Stefanadis, C. Novel sodium channel SCN5A mutations in Brugada syndrome patients from Greece. Int. J. Cardiol., 2010, 145(1), 45-48.
119. Samani, K.; Ai, T.; Towbin, J.A.; Brugada, R.; Shuraih, M.; Xi, Y.; Wu, G.; Cheng, J.; Vatta, M. A nonsense SCN5A mutation associated with Brugada-type electrocardiogram and intraventricular conduction defects. Pacing Clin. Electrophysiol., 2009, 32(9), 1231-1236.
120. Tfelt-Hansen, J.; Jespersen, T.; Hofman-Bang, J.; Rasmussen, H.B.; Cedergreen, P.; Skovby, F.; Abriel, H.; Svendsen, J.H.; Olesen, S.P.; Christiansen, M.; Haunso, S. Ventricular tachycardia in a Brugada syndrome patient caused by a novel deletion in SCN5A. Can. J. Cardiol., 2009, 25(3), 156-160.
121. Crotti, L.; Pedrazzini, M.; Insolia, R.; Cuoretti, A.; Ghidoni, A.; Dagradi, F.; Taravelli, E.; Chieffo, E.; Vicentini, A.; Schwartz, P.J. Novel human pathological mutations. Gene symbol: SCN5A. Disease: Brugada Syndrome. Hum. Genet., 2009, 126(2), 339.
122. Casini, S.; Tan, H.L.; Bhuiyan, Z.A.; Bezzina, C.R.; Barnett, P.; Cerbai, E.; Mugelli, A.; Wilde, A.A.; Veldkamp, M.W. Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation. Cardiovasc. Res., 2007, 76(3), 418-429.
123. Lee, Y.S.; Baek, J.S.; Kim, S.Y.; Seo, S.W.; Kwon, B.S.; Kim, G.B.; Bae, E.J.; Park, S.S.; Noh, C.I. Childhood brugada syndrome in two korean families. Korean Circ. J., 2010, 40(3), 143-147.
124. Napolitano, C.; Priori, S.G.; Schwartz, P.J.; Bloise, R.; Ronchetti, E.; Nastoli, J.; Bottelli, G.; Cerrone, M.; Leonardi, S. Genetic test ing in the long QT syndrome: Development and validation of an efficient approach to genotyping in clinical practice. JAMA, 2005, 294(23), 2975-2980.
125. Priori, S.G.; Schwartz, P.J.; Napolitano, C.; Bloise, R.; Ronchetti, E.; Grillo, M.; Vicentini, A.; Spazzolini, C.; Nastoli, J.; Bottelli, G.; Folli, R.; Cappelletti, D. Risk stratification in the long-QT syndrome. N. Engl. J. Med., 2003, 348(19), 1866-1874.
126. Priori, S.G.; Napolitano, C.; Schwartz, P.J.; Grillo, M.; Bloise, R.; Ronchetti, E.; Moncalvo, C.; Tulipani, C.; Veia, A.; Bottelli, G.; Nastoli, J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA, 2004, 292(11), 1341-1344.
127. Zipes, D.P.; Camm, A.J.; Borggrefe, M.; Buxton, A.E.; Chaitman, B.; Fromer, M.; Gregoratos, G.; Klein, G.; Moss, A.J.; Myerburg, R.J.; Priori, S.G.; Quinones, M.A.; Roden, D.M.; Silka, M.J.; Tracy, C.; Smith, S.C., Jr.; Jacobs, A.K.; Adams, C.D.; Antman, E.M.; Anderson, J.L.; Hunt, S.A.; Halperin, J.L.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B.; Blanc, J.J.; Budaj, A.; Dean, V.; Deckers, J.W.; Despres, C.; Dickstein, K.; Lekakis, J.; McGregor, K.; Metra, M.; Morais, J.; Osterspey, A.; Tamargo, J.L.; Zamorano, J.L. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006, 114(10), e385-484. (Pubitemid 44362500)
128. Wang, D.W.; Crotti, L.; Shimizu, W.; Pedrazzini, M.; Cantu, F.; De Filippo, P.; Kishiki, K.; Miyazaki, A.; Ikeda, T.; Schwartz, P.J.; George, A.L., Jr. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ. Arrhythm. Electrophysiol., 2008, 1(5), 370-378.
129. Yamamura, K.; Muneuchi, J.; Uike, K.; Ikeda, K.; Inoue, H.; Takahata, Y.; Shiokawa, Y.; Yoshikane, Y.; Makiyama, T.; Horie, M.; Hara, T. A novel SCN5A mutation associated with the linker between III and IV domains of Na(v)1.5 in a neonate with fatal long QT syndrome. Int. J. Cardiol., 2010, 145(1), 61-64.
130. Silver, E.S.; Liberman, L.; Chung, W.K.; Spotnitz, H.M.; Chen, J.M.; Ackerman, M.J.; Moir, C.; Hordof, A.J.; Pass, R.H. Long QT syndrome due to a novel mutation in SCN5A: Treatment with ICD placement at 1 month and left cardiac sympathetic denervation at 3 months of age. J. Interv. Card. Electrophysiol., 2009, 26(1), 41-45.
131. Li, Q.; Huang, H.; Liu, G.; Lam, K.; Rutberg, J.; Green, M.S.; Birnie, D.H.; Lemery, R.; Chahine, M.; Gollob, M.H. Gain-offunction mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochem. Biophys. Res. Commun., 2009, 380(1), 132-137.
132. Letsas, K.P.; Sideris, A.; Efremidis, M.; Pappas, L.K.; Gavrielatos, G.; Filippatos, G.S.; Kardaras, F. Prevalence of paroxysmal atrial fibrillation in Brugada syndrome: A case series and a review of the literature. J. Cardiovasc. Med. (Hagerstown), 2007, 8(10), 803-806.
133. Makiyama, T.; Akao, M.; Shizuta, S.; Doi, T.; Nishiyama, K.; Oka, Y.; Ohno, S.; Nishio, Y.; Tsuji, K.; Itoh, H.; Kimura, T.; Kita, T.; Horie, M. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J. Am. Coll. Cardiol., 2008, 52(16), 1326-1334.
134. Darbar, D.; Kannankeril, P.J.; Donahue, B.S.; Kucera, G.; Stubblefield, T.; Haines, J.L.; George, A.L., Jr.; Roden, D.M. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation, 2008, 117(15), 1927-1935.
135. Schwartz, P.J.; Priori, S.G.; Bloise, R.; Napolitano, C.; Ronchetti, E.; Piccinini, A.; Goj, C.; Breithardt, G.; Schulze-Bahr, E.; Wedekind, H.; Nastoli, J. Molecular diagnosis in a child with sudden infant death syndrome. Lancet, 2001, 358(9290), 1342-1343.
136. Christiansen, M.; Tonder, N.; Larsen, L.A.; Andersen, P.S.; Simonsen, H.; Oyen, N.; Kanters, J.K.; Jacobsen, J.R.; Fosdal, I.; Wettrell, G.; Kjeldsen, K. Mutations in the HERG K+-ion channel: A novel link between long QT syndrome and sudden infant death syndrome. Am. J. Cardiol., 2005, 95(3), 433-434.
137. Miller, T.E.; Estrella, E.; Myerburg, R.J.; Garcia de Viera, J.; Moreno, N.; Rusconi, P.; Ahearn, M.E.; Baumbach, L.; Kurlansky, P.; Wolff, G.; Bishopric, N.H. Recurrent third-trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation, 2004, 109(24), 3029-3034.
138. Arnestad, M.; Crotti, L.; Rognum, T.O.; Insolia, R.; Pedrazzini, M.; Ferrandi, C.; Vege, A.; Wang, D.W.; Rhodes, T.E.; George, A.L., Jr.; Schwartz, P.J. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation, 2007, 115(3), 361-367. (Pubitemid 46148510)
139. Wang, D.W.; Desai, R.R.; Crotti, L.; Arnestad, M.; Insolia, R.; Pedrazzini, M.; Ferrandi, C.; Vege, A.; Rognum, T.; Schwartz, P.J.; George, A.L., Jr. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation, 2007, 115(3), 368-376. (Pubitemid 46148511)
140. Tan, B.H.; Pundi, K.N.; Van Norstrand, D.W.; Valdivia, C.R.; Tester, D.J.; Medeiros-Domingo, A.; Makielski, J.C.; Ackerman, M.J. Sudden infant death syndrome-associated mutations in the sodium channel beta subunits. Heart Rhythm, 7(6), 771-778.
141. Milanesi, R.; Baruscotti, M.; Gnecchi-Ruscone, T.; DiFrancesco, D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N. Engl. J. Med., 2006, 354(2), 151-157.
142. Schulze-Bahr, E.; Neu, A.; Friederich, P.; Kaupp, U.B.; Breithardt, G.; Pongs, O.; Isbrandt, D. Pacemaker channel dysfunction in a patient with sinus node disease. J. Clin. Invest., 2003, 111(10), 1537-1545.
143. Makita, N.; Behr, E.; Shimizu, W.; Horie, M.; Sunami, A.; Crotti, L.; Schulze-Bahr, E.; Fukuhara, S.; Mochizuki, N.; Makiyama, T.; Itoh, H.; Christiansen, M.; McKeown, P.; Miyamoto, K.; Kamakura, S.; Tsutsui, H.; Schwartz, P.J.; George, A.L., Jr.; Roden, D.M. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J. Clin. Invest., 2008, 118(6), 2219-2229.
144. Viswanathan, P.C.; Balser, J.R. Inherited sodium channelopathies: A continuum of channel dysfunction. Trends. Cardiovasc. Med., 2004, 14(1), 28-35.
145. Bezzina, C.; Veldkamp, M.W.; van Den Berg, M.P.; Postma, A.V.; Rook, M.B.; Viersma, J.W.; van Langen, I.M.; Tan-Sindhunata, G.; Bink-Boelkens, M.T.; van Der Hout, A.H.; Mannens, M.M.; Wilde, A.A. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ. Res., 1999, 85(12), 1206-1213.
146. Remme, C.A.; Verkerk, A.O.; Nuyens, D.; van Ginneken, A.C.; van Brunschot, S.; Belterman, C.N.; Wilders, R.; van Roon, M.A.; Tan, H.L.; Wilde, A.A.; Carmeliet, P.; de Bakker, J.M.; Veldkamp, M.W.; Bezzina, C.R. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation, 2006, 114(24), 2584-2594.
147. Tan, B.H.; Valdivia, C.R.; Song, C.; Makielski, J.C. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine. Am. J. Physiol. Heart Circ. Physiol.,
148. Oliva, A.; Hu, D.; Viskin, S.; Carrier, T.; Cordeiro, J.M.; Barajas- Martinez, H.; Wu, Y.; Burashnikov, E.; Brugada, R.; Rosso, R.; Guerchicoff, A.; Pollevick, G.; Pascali, V.L.; Antzelevitch, C. SCN5A Mutation associated with acute myocardial infarction. Leg. Med. (Tokyo), 2009, 11(Suppl 1), S206-209.
149. Ten Harkel, A.D.; Witsenburg, M.; de Jong, P.L.; Jordaens, L.; Wijman, M.; Wilde, A.A. Efficacy of an implantable cardioverterdefibrillator in a neonate with LQT3 associated arrhythmias. Europace, 2005, 7(1), 77-84.
150. Yamagishi, H.; Furutani, M.; Kamisago, M.; Morikawa, Y.; Kojima, Y.; Hino, Y.; Furutani, Y.; Kimura, M.; Imamura, S.; Takao, A.; Momma, K.; Matsuoka, R. A de novo missense mutation (R1623Q) of the SCN5A gene in a Japanese girl with sporadic long QT sydrome. Mutations in brief no. 140. Online. Hum. Mutat., 1998, 11(6), 481.
151. Zhang, T.; Yong, S.L.; Drinko, J.K.; Popovic, Z.B.; Shryock, J.C.; Belardinelli, L.; Wang, Q.K. LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice. Int. J. Cardiol., 2009, [Epub ahead of print].
152. Holst, A.G.; Calloe, K.; Jespersen, T.; Cedergreen, P.; Winkel, B.G.; Jensen, H.K.; Leren, T.P.; Haunso, S.; Svendsen, J.H.; Tfelt- Hansen, J. A Novel SCN5A Mutation in a Patient with Coexistence of Brugada Syndrome Traits and Ischaemic Heart Disease. Case Report Med., 2009, 2009, 963645.
153. Samani, K.; Wu, G.; Ai, T.; Shuraih, M.; Mathuria, N.S.; Li, Z.; Sohma, Y.; Purevjav, E.; Xi, Y.; Towbin, J.A.; Cheng, J.; Vatta, M. A novel SCN5A mutation V1340I in Brugada syndrome augmenting arrhythmias during febrile illness. Heart Rhythm, 2009, 6(9), 1318-1326.
154. Huang, H.; Millat, G.; Rodriguez-Lafrasse, C.; Rousson, R.; Kugener, B.; Chevalier, P.; Chahine, M. Biophysical characterization of a new SCN5A mutation S1333Y in a SIDS infant linked to long QT syndrome. FEBS Lett., 2009, 583(5), 890-896.
155. Tan, B.H.; Iturralde-Torres, P.; Medeiros-Domingo, A.; Nava, S.; Tester, D.J.; Valdivia, C.R.; Tusie-Luna, T.; Ackerman, M.J.; Makielski, J.C. A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia. Cardiovasc. Res., 2007, 76(3), 409-417.
156. Neu, A.; Eiselt, M.; Paul, M.; Sauter, K.; Stallmeyer, B.; Isbrandt, D.; Schulze-Bahr, E. A homozygous SCN5A mutation in a severe, recessive type of cardiac conduction disease. Hum. Mutat., 31(8), E1609-1621.
157. Wallace, R.H.; Wang, D.W.; Singh, R.; Scheffer, I.E.; George, A.L., Jr.; Phillips, H.A.; Saar, K.; Reis, A.; Johnson, E.W.; Sutherland, G.R.; Berkovic, S.F.; Mulley, J.C. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat. Genet., 1998, 19(4), 366-370.
158. Medeiros-Domingo, A.; Kaku, T.; Tester, D.J.; Iturralde-Torres, P.; Itty, A.; Ye, B.; Valdivia, C.; Ueda, K.; Canizales-Quinteros, S.; Tusie-Luna, M.T.; Makielski, J.C.; Ackerman, M.J. SCN4Bencoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation, 2007, 116(2), 134-142.
159. Watanabe, H.; Koopmann, T.T.; Le Scouarnec, S.; Yang, T.; Ingram, C.R.; Schott, J.J.; Demolombe, S.; Probst, V.; Anselme, F.; Escande, D.; Wiesfeld, A.C.; Pfeufer, A.; Kaab, S.; Wichmann, H.E.; Hasdemir, C.; Aizawa, Y.; Wilde, A.A.; Roden, D.M.; Bezzina, C.R. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Invest., 2008, 118(6), 2260-2268.
160. Watanabe, H.; Darbar, D.; Kaiser, D.W.; Jiramongkolchai, K.; Chopra, S.; Donahue, B.S.; Kannankeril, P.J.; Roden, D.M. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ. Arrhythm. Electrophysiol., 2009, 2(3), 268-275.
161. Hakim, P.; Brice, N.; Thresher, R.; Lawrence, J.; Zhang, Y.; Jackson, A.P.; Grace, A.A.; Huang, C.L. Scn3b knockout mice exhibit abnormal sino-atrial and cardiac conduction properties. Acta Physiol. (Oxf), 2010, 198(1), 47-59.
162. Hu, D.; Barajas-Martinez, H.; Burashnikov, E.; Springer, M.; Wu, Y.; Varro, A.; Pfeiffer, R.; Koopmann, T.T.; Cordeiro, J.M.; Guerchicoff, A.; Pollevick, G.D.; Antzelevitch, C. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ. Cardiovasc. Genet., 2009, 2(3), 270-278.
163. Nicholson, E.; Randall, A.D. Na(v)1.5 sodium channels in a human microglial cell line. J. Neuroimmunol., 2009, 215(1-2), 25-30.
164. Candenas, L.; Seda, M.; Noheda, P.; Buschmann, H.; Cintado, C.G.; Martin, J.D.; Pinto, F.M. Molecular diversity of voltagegated sodium channel alpha and beta subunit mRNAs in human tissues. Eur. J. Pharmacol., 2006, 541(1-2), 9-16.
165. Hartmann, H.A.; Colom, L.V.; Sutherland, M.L.; Noebels, J.L. Selective localization of cardiac SCN5A sodium channels in limbic regions of rat brain. Nat. Neurosci., 1999, 2(7), 593-595.
166. Ou, S.W.; Kameyama, A.; Hao, L.Y.; Horiuchi, M.; Minobe, E.; Wang, W.Y.; Makita, N.; Kameyama, M. Tetrodotoxin-resistant Na+ channels in human neuroblastoma cells are encoded by new variants of Nav1.5/SCN5A. Eur. J. Neurosci., 2005, 22(4), 793-801.
167. Wang, J.; Ou, S.W.; Wang, Y.J.; Zong, Z.H.; Lin, L.; Kameyama, M.; Kameyama, A. New variants of Nav1.5/SCN5A encode Na+ channels in the brain. J. Neurogenet., 2008, 22(1), 57-75.
168. Wu, L.; Nishiyama, K.; Hollyfield, J.G.; Wang, Q. Localization of Nav1.5 sodium channel protein in the mouse brain. Neuroreport, 2002, 13(18), 2547-2551.
169. Wang, J.; Ou, S.W.; Wang, Y.J.; Kameyama, M.; Kameyama, A.; Zong, Z.H. Analysis of four novel variants of Nav1.5/SCN5A cloned from the brain. Neurosci. Res., 2009, 64(4), 339-347.
170. Felts, P.A.; Yokoyama, S.; Dib-Hajj, S.; Black, J.A.; Waxman, S.G. Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): Different expression patterns in developing rat nervous system. Brain Res. Mol. Brain Res., 1997, 45(1), 71-82.
171. Dib-Hajj, S.; Black, J.A.; Felts, P.; Waxman, S.G. Down-regulation of transcripts for Na channel alpha-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA, 1996, 93(25), 14950-14954.
172. Waxman, S.G.; Kocsis, J.D.; Black, J.A. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J. Neurophysiol., 1994, 72(1), 466-470.
173. Xiao, H.S.; Huang, Q.H.; Zhang, F.X.; Bao, L.; Lu, Y.J.; Guo, C.; Yang, L.; Huang, W.J.; Fu, G.; Xu, S.H.; Cheng, X.P.; Yan, Q.; Zhu, Z.D.; Zhang, X.; Chen, Z.; Han, Z.G. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc. Natl. Acad. Sci. USA, 2002, 99(12), 8360-8365.
174. Kim, C.H.; Oh, Y.; Chung, J.M.; Chung, K. The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res. Mol. Brain Res., 2001, 95(1-2), 153-161.
175. Dib-Hajj, S.D.; Fjell, J.; Cummins, T.R.; Zheng, Z.; Fried, K.; LaMotte, R.; Black, J.A.; Waxman, S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain, 1999, 83(3), 591-600.
176. Hains, B.C.; Saab, C.Y.; Klein, J.P.; Craner, M.J.; Waxman, S.G. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J. Neurosci., 2004, 24(20), 4832-4839.
177. Lindia, J.A.; Kohler, M.G.; Martin, W.J.; Abbadie, C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain, 2005, 117(1-2), 145-153.
178. Hong, S.; Morrow, T.J.; Paulson, P.E.; Isom, L.L.; Wiley, J.W. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J. Biol. Chem., 2004, 279(28), 29341-29350.
179. Garry, E.M.; Delaney, A.; Anderson, H.A.; Sirinathsinghji, E.C.; Clapp, R.H.; Martin, W.J.; Kinchington, P.R.; Krah, D.L.; Abbadie, C.; Fleetwood-Walker, S.M. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain, 2005, 118(1-2), 97-111.
180. Nassar, M.A.; Baker, M.D.; Levato, A.; Ingram, R.; Mallucci, G.; McMahon, S.B.; Wood, J.N. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain, 2006, 2, 33.
181. Boiko, T.; Rasband, M.N.; Levinson, S.R.; Caldwell, J.H.; Mandel, G.; Trimmer, J.S.; Matthews, G. Compact myelin dictates the differential targeting of two sodium channel isoforms in the same axon. Neuron, 2001, 30(1), 91-104.
182. Caldwell, J.H.; Schaller, K.L.; Lasher, R.S.; Peles, E.; Levinson, S.R. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5616-5620.
183. Raman, I.M.; Bean, B.P. Resurgent sodium current and action potential formation in dissociated cerebellar Purkinje neurons. J. Neurosci., 1997, 17(12), 4517-4526.
184. Raman, I.M.; Sprunger, L.K.; Meisler, M.H.; Bean, B.P. Altered subthreshold sodium currents and disrupted firing patterns in Purkinje neurons of Scn8a mutant mice. Neuron, 1997, 19(4), 881-891.
185. Chen, Y.; Yu, F.H.; Sharp, E.M.; Beacham, D.; Scheuer, T.; Catterall, W.A. Functional properties and differential neuromodulation of Na(v)1.6 channels. Mol. Cell Neurosci., 2008, 38(4), 607-615.
186. Smith, M.R.; Smith, R.D.; Plummer, N.W.; Meisler, M.H.; Goldin, A.L. Functional analysis of the mouse Scn8a sodium channel. J. Neurosci., 1998, 18(16), 6093-6102.
187. Mercer, J.N.; Chan, C.S.; Tkatch, T.; Held, J.; Surmeier, D.J. Nav1.6 sodium channels are critical to pacemaking and fast spiking in globus pallidus neurons. J. Neurosci., 2007, 27(49), 13552-13566.
188. Mackenzie, F.E.; Parker, A.; Parkinson, N.J.; Oliver, P.L.; Brooker, D.; Underhill, P.; Lukashkina, V.A.; Lukashkin, A.N.; Holmes, C.; Brown, S.D. Analysis of the mouse mutant Cloth-ears shows a role for the voltage-gated sodium channel Scn8a in peripheral neural hearing loss. Genes Brain Behav., 2009, 8(7), 699-713.
189. Klugbauer, N.; Lacinova, L.; Flockerzi, V.; Hofmann, F. Structure and functional expression of a new member of the tetrodotoxinsensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J., 1995, 14(6), 1084-1090.
190. Toledo-Aral, J.J.; Moss, B.L.; He, Z.J.; Koszowski, A.G.; Whisenand, T.; Levinson, S.R.; Wolf, J.J.; Silos-Santiago, I.; Halegoua, S.; Mandel, G. Identification of PN1, a predominant voltagedependent sodium channel expressed principally in peripheral neurons. Proc. Natl. Acad. Sci. USA, 1997, 94(4), 1527-1532.
191. Cummins, T.R.; Howe, J.R.; Waxman, S.G. Slow closed-state inactivation: A novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J. Neurosci., 1998, 18(23), 9607-9619.
192. Waxman, S.G. Nav1.7, its mutations, and the syndromes that they cause. Neurology, 2007, 69(6), 505-507.
193. Cummins, T.R.; Dib-Hajj, S.D.; Waxman, S.G. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci., 2004, 24(38), 8232-8236.
194. Renganathan, M.; Cummins, T.R.; Waxman, S.G. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol., 2001, 86(2), 629-640.
195. Silverman, F.N.; Gilden, J.J. Congenital insensitivity to pain: A neurologic syndrome with bizarre skeletal lesions. Radiology, 1959, 72(2), 176-190.
196. Ahmad, S.; Dahllund, L.; Eriksson, A.B.; Hellgren, D.; Karlsson, U.; Lund, P.E.; Meijer, I.A.; Meury, L.; Mills, T.; Moody, A.; Morinville, A.; Morten, J.; O'Donnell, D.; Raynoschek, C.; Salter, H.; Rouleau, G.A.; Krupp, J.J. A stop codon mutation in SCN9A causes lack of pain sensation. Hum. Mol. Genet., 2007, 16(17), 2114-2121.
197. Diatchenko, L.; Nackley, A.G.; Tchivileva, I.E.; Shabalina, S.A.; Maixner, W. Genetic architecture of human pain perception. Trends Genet., 2007, 23(12), 605-613.
198. Estacion, M.; Harty, T.P.; Choi, J.S.; Tyrrell, L.; Dib-Hajj, S.D.; Waxman, S.G. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann. Neurol., 2009, 66(6), 862-866.
199. Reimann, F.; Cox, J.J.; Belfer, I.; Diatchenko, L.; Zaykin, D.V.; McHale, D.P.; Drenth, J.P.; Dai, F.; Wheeler, J.; Sanders, F.; Wood, L.; Wu, T.X.; Karppinen, J.; Nikolajsen, L.; Mannikko, M.; Max, M.B.; Kiselycznyk, C.; Poddar, M.; Te Morsche, R.H.; Smith, S.; Gibson, D.; Kelempisioti, A.; Maixner, W.; Gribble, F.M.; Woods, C.G. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc. Natl. Acad. Sci. USA, 2010, 107(11), 5148-5153.
200. Singh, N.A.; Pappas, C.; Dahle, E.J.; Claes, L.R.; Pruess, T.H.; De Jonghe, P.; Thompson, J.; Dixon, M.; Gurnett, C.; Peiffer, A.; White, H.S.; Filloux, F.; Leppert, M.F. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet., 2009, 5(9), e1000649.
201. Baker, M.D.; Bostock, H. Low-threshold, persistent sodium current in rat large dorsal root ganglion neurons in culture. J. Neurophysiol., 1997, 77(3), 1503-1513.
202. Decosterd, I.; Ji, R.R.; Abdi, S.; Tate, S.; Woolf, C.J. The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain, 2002, 96(3), 269-277.
203. Sleeper, A.A.; Cummins, T.R.; Dib-Hajj, S.D.; Hormuzdiar, W.; Tyrrell, L.; Waxman, S.G.; Black, J.A. Changes in expression of two tetrodotoxin- resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J. Neurosci., 2000, 20(19), 7279-7289.
204. Drenth, J.P.; Te Morsche, R.H.; Mansour, S.; Mortimer, P.S. Primary erythermalgia as a sodium channelopathy: Screening for SCN9A mutations: Exclusion of a causal role of SCN10A and SCN11A. Arch. Dermatol., 2008, 144(3), 320-324.
205. Loughney, K.; Kreber, R.; Ganetzky, B. Molecular analysis of the para locus, a sodium channel gene in Drosophila. Cell, 1989, 58(6), 1143-1154.
206. Littleton, J.T.; Ganetzky, B. Ion channels and synaptic organization: Analysis of the Drosophila genome. Neuron, 2000, 26(1), 35-43.
207. Feng, G.; Deak, P.; Chopra, M.; Hall, L.M. Cloning and functional analysis of TipE, a novel membrane protein that enhances Drosophila para sodium channel function. Cell, 1995, 82(6), 1001-1011.
208. Warmke, J.W.; Reenan, R.A.; Wang, P.; Qian, S.; Arena, J.P.; Wang, J.; Wunderler, D.; Liu, K.; Kaczorowski, G.J.; Van der Ploeg, L.H.; Ganetzky, B.; Cohen, C.J. Functional expression of Drosophila para sodium channels. Modulation by the membrane protein TipE and toxin pharmacology. J. Gen. Physiol., 1997, 110(2), 119-133.
209. Elliott M. In:Synthetic Pyrethroids , Elliott M, ed. American Chem Soc: Washington, 1977, pp.1-28
210. Narahashi, T. Neuroreceptors and ion channels as the basis for drug action: Past, present, and future. J. Pharmacol. Exp. Ther., 2000, 294(1), 1-26.
211. Raymond-Delpech, V.; Matsuda, K.; Sattelle, B.M.; Rauh, J.J.; Sattelle, D.B. Ion channels: Molecular targets of neuroactive insecticides. Invert. Neurosci., 2005, 5(3-4), 119-133.
212. Dong, K. Insect sodium channels and insecticide resistance. Invert. Neurosci., 2007, 7(1), 17-30.
213. Soderlund, D.M.; Knipple, D.C. The molecular biology of knockdown resistance to pyrethroid insecticides. Insect Biochem. Mol. Biol., 2003, 33(6), 563-577.
214. Soderlund, D.M. Pyrethroids, knockdown resistance and sodium channels. Pest Manag. Sci., 2008, 64(6), 610-616.
215. Choi, J.S.; Soderlund, D.M. Structure-activity relationships for the action of 11 pyrethroid insecticides on rat Na v 1.8 sodium channels expressed in Xenopus oocytes. Toxicol. Appl. Pharmacol., 2006, 211(3), 233-244.
216. Smith, T.J.; Soderlund, D.M. Action of the pyrethroid insecticide cypermethrin on rat brain IIa sodium channels expressed in xenopus oocytes. Neurotoxicology, 1998, 19(6), 823-832.
217. Tatebayashi, H.; Narahashi, T. Differential mechanism of action of the pyrethroid tetramethrin on tetrodotoxin-sensitive and tetrodotoxin- resistant sodium channels. J. Pharmacol. Exp. Ther., 1994, 270(2), 595-603.
218. Wang, S.Y.; Barile, M.; Wang, G.K. A phenylalanine residue at segment D3-S6 in Nav1.4 voltage-gated Na(+) channels is critical for pyrethroid action. Mol. Pharmacol., 2001, 60(3), 620-628.
219. Cestele, S.; Catterall, W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie, 2000, 82(9- 10), 883-892.
220. Billen, B.; Bosmans, F.; Tytgat, J. Animal peptides targeting voltage- activated sodium channels. Curr. Pharm. Des., 2008, 14(24), 2492-2502.
221. Bosmans, F.; Tytgat, J. Sea anemone venom as a source of insecticidal peptides acting on voltage-gated Na+ channels. Toxicon, 2007, 49(4), 550-560.
222. Wanke, E.; Zaharenko, A.J.; Redaelli, E.; Schiavon, E. Actions of sea anemone type 1 neurotoxins on voltage-gated sodium channel isoforms. Toxicon, 2009, 54(8), 1102-1111.
223. Catterall, W.A.; Cestele, S.; Yarov-Yarovoy, V.; Yu, F.H.; Konoki, K.; Scheuer, T. Voltage-gated ion channels and gating modifier toxins. Toxicon, 2007, 49(2), 124-141.
224. Cohen, L.; Troub, Y.; Turkov, M.; Gilles, N.; Ilan, N.; Benveniste, M.; Gordon, D.; Gurevitz, M. Mammalian skeletal muscle voltagegated sodium channels are affected by scorpion depressant "insectselective" toxins when preconditioned. Mol. Pharmacol., 2007, 72(5), 1220-1227.
225. Heinemann, S.H.; Leipold, E. Conotoxins of the O-superfamily affecting voltage-gated sodium channels. Cell Mol. Life Sci., 2007, 64(11), 1329-1340.
226. McDonough, S.I. Gating modifier toxins of voltage-gated calcium channels. Toxicon, 2007, 49(2), 202-212.
227. Oliveira, J.S.; Redaelli, E.; Zaharenko, A.J.; Cassulini, R.R.; Konno, K.; Pimenta, D.C.; Freitas, J.C.; Clare, J.J.; Wanke, E. Binding specificity of sea anemone toxins to Nav 1.1-1.6 sodium channels: Unexpected contributions from differences in the IV/S3- S4 outer loop. J. Biol. Chem., 2004, 279(32), 33323-33335.
228. Leipold, E.; Hansel, A.; Borges, A.; Heinemann, S.H. Subtype specificity of scorpion beta-toxin Tz1 interaction with voltagegated sodium channels is determined by the pore loop of domain 3. Mol. Pharmacol., 2006, 70(1), 340-347.
229. Yuan, Y.; Luo, L.; Peigneur, S.; Tytgat, J.; Zhu, S. Two recombinant depressant scorpion neurotoxins differentially affecting mammalian sodium channels. Toxicon, 2010, 55(8), 1425-1433.
230. Kahn, R.; Karbat, I.; Ilan, N.; Cohen, L.; Sokolov, S.; Catterall, W.A.; Gordon, D.; Gurevitz, M. Molecular requirements for recognition of brain voltage-gated sodium channels by scorpion alphatoxins. J. Biol. Chem., 2009, 284(31), 20684-20691.
231. Gordon, D.; Karbat, I.; Ilan, N.; Cohen, L.; Kahn, R.; Gilles, N.; Dong, K.; Stuhmer, W.; Tytgat, J.; Gurevitz, M. The differential preference of scorpion alpha-toxins for insect or mammalian sodium channels: Implications for improved insect control. Toxicon, 2007, 49(4), 452-472.
232. Bosmans, F.; Tytgat, J. Voltage-gated sodium channel modulation by scorpion alpha-toxins. Toxicon, 2007, 49(2), 142-158.
233. Barbier, J.; Lamthanh, H.; Le Gall, F.; Favreau, P.; Benoit, E.; Chen, H.; Gilles, N.; Ilan, N.; Heinemann, S.H.; Gordon, D.; Menez, A.; Molgo, J. A delta-conotoxin from Conus ermineus venom inhibits inactivation in vertebrate neuronal Na+ channels but not in skeletal and cardiac muscles. J. Biol. Chem., 2004, 279(6), 4680-4685.
234. Lewis, R.J.; Schroeder, C.I.; Ekberg, J.; Nielsen, K.J.; Loughnan, M.; Thomas, L.; Adams, D.A.; Drinkwater, R.; Adams, D.J.; Alewood, P.F. Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. Mol. Pharmacol., 2007, 71(3), 676-685.
235. Yao, S.; Zhang, M.M.; Yoshikami, D.; Azam, L.; Olivera, B.M.; Bulaj, G.; Norton, R.S. Structure, dynamics, and selectivity of the sodium channel blocker mu-conotoxin SIIIA. Biochemistry, 2008, 47(41), 10940-10949.
236. Yamaji, N.; Little, M.J.; Nishio, H.; Billen, B.; Villegas, E.; Nishiuchi, Y.; Tytgat, J.; Nicholson, G.M.; Corzo, G. Synthesis, solution structure, and phylum selectivity of a spider delta-toxin that slows inactivation of specific voltage-gated sodium channel subtypes. J. Biol. Chem., 2009, 284(36), 24568-24582.
237. Bosmans, F.; Rash, L.; Zhu, S.; Diochot, S.; Lazdunski, M.; Escoubas, P.; Tytgat, J. Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes. Mol. Pharmacol., 2006, 69(2), 419-429.
238. Priest, B.T.; Blumenthal, K.M.; Smith, J.J.; Warren, V.A.; Smith, M.M. ProTx-I and ProTx-II: Gating modifiers of voltage-gated sodium channels. Toxicon, 2007, 49(2), 194-201.
239. Smith, J.J.; Alphy, S.; Seibert, A.L.; Blumenthal, K.M. Differential phospholipid binding by site 3 and site 4 toxins. Implications for structural variability between voltage-sensitive sodium channel domains. J. Biol. Chem., 2005, 280(12), 11127-11133.
240. Middleton, R.E.; Warren, V.A.; Kraus, R.L.; Hwang, J.C.; Liu, C.J.; Dai, G.; Brochu, R.M.; Kohler, M.G.; Gao, Y.D.; Garsky, V.M.; Bogusky, M.J.; Mehl, J.T.; Cohen, C.J.; Smith, M.M. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry, 2002, 41(50), 14734-14747.
241. Hoyt, S.B.; London, C.; Gorin, D.; Wyvratt, M.J.; Fisher, M.H.; Abbadie, C.; Felix, J.P.; Garcia, M.L.; Li, X.; Lyons, K.A.; McGowan, E.; MacIntyre, D.E.; Martin, W.J.; Priest, B.T.; Ritter, A.; Smith, M.M.; Warren, V.A.; Williams, B.S.; Kaczorowski, G.J.; Parsons, W.H. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: Potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett., 2007, 17(16), 4630-4634.
242. Smith, J.J.; Cummins, T.R.; Alphy, S.; Blumenthal, K.M. Molecular interactions of the gating modifier toxin ProTx-II with NaV 1.5: Implied existence of a novel toxin binding site coupled to activation. J. Biol. Chem., 2007, 282(17), 12687-12697.
243. Sokolov, S.; Kraus, R.L.; Scheuer, T.; Catterall, W.A. Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II. Mol. Pharmacol., 2008, 73(3), 1020-1028.
244. Schmalhofer, W.A.; Calhoun, J.; Burrows, R.; Bailey, T.; Kohler, M.G.; Weinglass, A.B.; Kaczorowski, G.J.; Garcia, M.L.; Koltzenburg, M.; Priest, B.T. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol., 2008, 74(5), 1476-1484.
245. Kinoshita, E.; Maejima, H.; Yamaoka, K.; Konno, K.; Kawai, N.; Shimizu, E.; Yokote, S.; Nakayama, H.; Seyama, I. Novel wasp toxin discriminates between neuronal and cardiac sodium channels. Mol. Pharmacol., 2001, 59(6), 1457-1463.
246. Schiavon, E.; Stevens, M.; Zaharenko, A.J.; Konno, K.; Tytgat, J.; Wanke, E. Voltage-gated sodium channel isoform-specific effects of pompilidotoxins. FEBS J., 2010, 277(4), 918-930.
247. Zuliani, V.; Patel, M.K.; Fantini, M.; Rivara, M. Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr. Top. Med. Chem., 2009, 9(4), 396-415.
248. Matulenko, M.A.; Scanio, M.J.; Kort, M.E. Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr. Top. Med. Chem., 2009, 9(4), 362-376.
249. Beaudoin, S.; Johnson, M.S.; Marron, B.E.; Suto, M.J. Sodium channel inhibitors. W.I.P.O Patent 2009012241, January 22, 2009.
250. Fulp, A.B.; Johnson, M.S.; Markworth, C.J.; Marron, B.E.; Seconi, D.C.; West, C.W.; Wang, X.; Zhou, S. Sodium Channel Inhibitors. W.I.P.O Patent 2009012242, January 22, 2009.
251. Priest, B.T. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr. Opin. Drug Discov. Devel., 2009, 12(5), 682-692.
252. Rosker, C.; Lohberger, B.; Hofer, D.; Steinecker, B.; Quasthoff, S.; Schreibmayer, W. The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am. J. Physiol. Cell Physiol., 2007, 293(2), C783-789.
253. Williams, B.S.; Felix, J.P.; Priest, B.T.; Brochu, R.M.; Dai, K.; Hoyt, S.B.; London, C.; Tang, Y.S.; Duffy, J.L.; Parsons, W.H.; Kaczorowski, G.J.; Garcia, M.L. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry, 2007, 46(50), 14693-14703.
254. Fraser, R., A.; Sherrington, R.; Macdonald, M. L.; Samuels, M.; Newman, S.; Fu, J.-M.; Kamboj, R. Potent and selective Nav1.7 sodium channel blockers, W.I.P.O Patent 2007109324, September 27, 2007.
255. Hoyt, S.B.; London, C.; Ok, H.; Gonzalez, E.; Duffy, J.L.; Abbadie, C.; Dean, B.; Felix, J.P.; Garcia, M.L.; Jochnowitz, N.; Karanam, B.V.; Li, X.; Lyons, K.A.; McGowan, E.; Macintyre, D.E.; Martin, W.J.; Priest, B.T.; Smith, M.M.; Tschirret-Guth, R.; Warren, V.A.; Williams, B.S.; Kaczorowski, G.J.; Parsons, W.H. Benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett., 2007, 17(22), 6172-6177.
256. London, C.; Hoyt, S.B.; Parsons, W.H.; Williams, B.S.; Warren, V.A.; Tschirret-Guth, R.; Smith, M.M.; Priest, B.T.; McGowan, E.; Martin, W.J.; Lyons, K.A.; Li, X.; Karanam, B.V.; Jochnowitz, N.; Garcia, M.L.; Felix, J.P.; Dean, B.; Abbadie, C.; Kaczorowski, G.J.; Duffy, J.L. Imidazopyridines: A novel class of hNav1.7 channel blockers. Bioorg. Med. Chem. Lett., 2008, 18(5), 1696-1701.
257. Jarvis, M.F.; Honore, P.; Shieh, C.C.; Chapman, M.; Joshi, S.; Zhang, X.F.; Kort, M.; Carroll, W.; Marron, B.; Atkinson, R.; Thomas, J.; Liu, D.; Krambis, M.; Liu, Y.; McGaraughty, S.; Chu, K.; Roeloffs, R.; Zhong, C.; Mikusa, J.P.; Hernandez, G.; Gauvin, D.; Wade, C.; Zhu, C.; Pai, M.; Scanio, M.; Shi, L.; Drizin, I.; Gregg, R.; Matulenko, M.; Hakeem, A.; Gross, M.; Johnson, M.; Marsh, K.; Wagoner, P.K.; Sullivan, J.P.; Faltynek, C.R.; Krafte, D.S. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. USA, 2007, 104(20), 8520-8525.
258. Kort, M.E.; Drizin, I.; Gregg, R.J.; Scanio, M.J.; Shi, L.; Gross, M.F.; Atkinson, R.N.; Johnson, M.S.; Pacofsky, G.J.; Thomas, J.B.; Carroll, W.A.; Krambis, M.J.; Liu, D.; Shieh, C.C.; Zhang, X.; Hernandez, G.; Mikusa, J.P.; Zhong, C.; Joshi, S.; Honore, P.; Roeloffs, R.; Marsh, K.C.; Murray, B.P.; Liu, J.; Werness, S.; Faltynek, C.R.; Krafte, D.S.; Jarvis, M.F.; Chapman, M.L.; Marron, B.E. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem., 2008, 51(3), 407-416.
259. Dekker, L.V.; Daniels, Z.; Hick, C.; Elsegood, K.; Bowden, S.; Szestak, T.; Burley, J.R.; Southan, A.; Cronk, D.; James, I.F. Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells. Eur. J. Pharmacol., 2005, 528(1-3), 52-58.
260. Veneroni, O.; Maj, R.; Calabresi, M.; Faravelli, L.; Fariello, R.G.; Salvati, P. Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain, 2003, 102(1-2), 17-25.
261. Sheets, P.L.; Heers, C.; Stoehr, T.; Cummins, T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther., 2008, 326(1), 89-99.
262. Weiser, T.; Wilson, N. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. Mol. Pharmacol., 2002, 62(3), 433-438.
263. Kahlig, K.M.; Lepist, I.; Leung, K.; Rajamani, S.; George, A.L., Jr. Ranolazine selectively blocks persistent current evoked by epilepsy- associated Na1.1 mutations. Br. J. Pharmacol., 2010, 161(6), 1414-1426.
264. Estacion, M.; Waxman, S.G.; Dib-Hajj, S.D. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol. Pain, 2010, 6, 35.